Pharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome

Agreement Marks Milestone in Pharmalink's Corporate Development

STOCKHOLM, June 30, 2010 - Pharmalink AB, today announced that it has closed its
agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R)
programme for the treatment of post-polio syndrome (PPS). The parties had
previously announced reaching an agreement whereby Grifols would acquire all
know-how and global intellectual property rights related to the use of human
immunoglobulin for the treatment of (PPS) - the concept at the heart of the
Xepol programme.

The agreement covers acquisition of one of Pharmalink's wholly
owned subsidiaries and includes inter alia US, EU and Japan patents for the
treatment of PPS with immunoglobulins, a US Orphan Drug Designation (ODD) for
the use of immunoglobulin for the treatment of PPS and documentation of a
number of clinical studies carried out in the recent years.

Johan Haggblad, Managing director of Pharmalink AB said: "This
agreement marks a significant milestone in Pharmalink's corporate
development. In developing a concept originally devised by academic
researchers at the Karolinska Institute and seeing it through to being
acquired by a world class company we have demonstrated the considerable value
creation made possible by the Pharmalink model. We are very happy to see
Grifols, our long standing partner, acquire and develop the PPS indication
and to have played a part in bringing forward a treatment for this
underserved condition."

Grifols will develop the PPS product opportunity using the
acquired assets. Pharmalink will assist in technology transfer and provide
contact with its network of physicians and patient organizations. The
purchase price is undisclosed but divided into an up-front payment and
commercial milestone payments.

The PPS product opportunity is an important means to provide a
treatment to a patient group largely suffering without effective medication
and to expand sales of immunoglobulin in new patient segments.

About PPS

Several decades after suffering acute polio infection
survivors commonly develop PPS characterized by new or increased muscle
weakness, fatigue, and pain. Ongoing denervation is the most often suggested
for increased muscle weakness associated with polio infection.

Patients with PPS have increased expression of mRNA for
proinflammatory cytokines in cerebrospinal fluid which suggests an
inflammatory process in the central nervous system. Some patients with
asymmetrical weakness have increased wear and tear on joints and muscles,
including breathing muscles.

While rarely fatal, the neurological and muscular symptoms of
PPS are lifelong and debilitating.

The most recent polio epidemic culminated in the Western countries
around 1950. As most infections occur in children, there is nowadays
a large pool of polio survivors with varying degrees of functional decline.
US National Institute of Neurological Disorders and Stroke (NINDS) gives a
prevalence interval for PPS of 25 to 50% (in primary polio infection
survivors), WHO estimates a 40 % prevalence; assuming a prevalence of 30%,
only in major Western countries there would be around 300,000 PPS patients.

Currently there is no pharmacological treatment for PPS.
Several therapeutic agents have failed in achieving positive outcomes.
Treatment practices are based on physiotherapy, non-fatiguing exercise and
the use of assistive devices. The promising results with immunoglobulin may
help address the unmet medical need of some PPS patients. In several clinical
trials lead by a team of physicians at Karolinska Institutet (Sweden) and
sponsored by Pharmalink AB, immunoglobulin has shown significant and
clinically meaningful results in endpoints such as pain, walking ability and
quality of life (SF-36 scores) by down-regulating the inflammatory process in
the nervous system of PPS patients.

About Pharmalink

Pharmalink is a Swedish specialty pharma company developing
high value products for niche indications. Pharmalink draws on its extensive
experience of pharmaceutical product development and the excellence of
medical science in Sweden to identify and progress products that address
significant unmet medical needs. Pharmalink has introduced more than 15
pharmaceutical products to the market. Using a repurposing and reformulation
strategy, Pharmalink minimizes the risk of product development. The Company's
strategy is to develop drugs to clinical proof-of-concept and then to
out-license or divest to a commercial partner. Pharmalink currently has two
clinical phase development projects, Nefecon(R) and BusulipoTM, mature for
out-licensing to a commercial partner and is actively in-licensing promising
new projects to add to its pipeline. Visit www.pharmalink.se for
further information.

About Grifols

Grifols is a Spanish holding company specialized in the
pharmaceutical-hospital sector and is present in more than 90 countries.
Since 2006, the company has been listed on the Spanish Stock Exchange
("Mercado Continuo") and is part of the Ibex-35. Currently it is the first
company in the European sector in plasma derivatives and the fourth in
production worldwide. In upcoming years, the company will strengthen its
leadership in the industry as a vertically integrated company, thanks to
recent investments. In terms of raw materials, Grifols has ensured its plasma
supply with 80 plasmapheresis centers in the United States and in terms of
fractionation, its plants in Barcelona (Spain) and Los Angeles (United
States) will allow the company to respond to the growing market demand.
Nevertheless, the company is preparing for sustained growth in the following
8-10 years and has launched an ambitious investment plan.

    For further information, please contact:

    Pharmalink AB:
    Johan Haggblad, Managing Director, +46(0)70-668-0644
    Email: johan.haggblad@pharmalink.se
    www.pharmalink.se

    Citigate Dewe Rogerson:
    Chris Gardner/Nina Enegren, +44-207-638-9571

    Grifols SA:
    Raquel Lumbreras Lanchas/Borja Gomez Vazquez
    Tel : +34-91-311-92-89/+34-91-311-92-90
    Mobile: +34-659-57-21-85
    Email: raquel_lumbreras@duomocomunicacion.com
           borja_gomez@duomocomunicacion.com

For further information, please contact: Pharmalink AB: Johan Haggblad, Managing Director, +46(0)70-668-0644, Email: johan.haggblad at pharmalink.se; Citigate Dewe Rogerson: Chris Gardner/Nina Enegren, +44-207-638-9571; Grifols SA: Raquel Lumbreras Lanchas/Borja Gomez Vazquez, Tel : +34-91-311-92-89/+34-91-311-92-90, Mobile: +34-659-57-21-85, Email: raquel_lumbreras at duomocomunicacion.com, borja_gomez at duomocomunicacion.com